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1 Drug description 
Generic/Brand name/ATC code:  
Axitinib, AG 013736 / Inlyta / no ATC code yet assigned 
Developer/Company: 
Pfizer 
Description: 
Axitinib is a tyrosine kinase inhibitor (TKI) designed to inhibit the tyrosine 
kinase activities of the vascular endothelial growth factor receptor (VEGFR) 
[1]. The VEGFR pathway plays an important role in the pathogenesis and 
progression of several tumour types and also in renal cell carcinoma (RCC). 
Signalling via VEGFR is involved in three key tumour processes namely, 
tumour growth, vascular angiogenesis and metastatic spread [1]. Additional 
to the VEGFR inhibition, axitinib also binds to and has low potency in 
platelet-derived growth factor receptor (PDGFR)-β and stem cell factor re-
ceptor (c-kit) [2]. 
The recommended daily dose of axitinib is 5mg twice daily administered 
orally [1]. In phase II and III clinical trials dosing of axitinib was either in-
creased or decreased (dose titration) based on the axitinib-related toxicity 
profile. If the treatment is well tolerated and no adverse events higher than 
Grade 2 according to the Common Terminology Criteria for Adverse Events 
(CTCAE) occurred for at least 2 weeks, the axitinib dose was stepwise in-
creased from 5mg twice daily to 7mg twice daily and subsequently to a 
maximum of 10mg twice daily. In case of severe adverse events the axitinib 
dose was first reduced to 3mg twice daily and then to 2mg twice daily [3-5]. 
2 Indication 
Axitinib for the second-line treatment of patients with advanced renal cell 
carcinoma (RCC). 
3 Current regulatory status 
Axitinib is not yet approved as an anticancer drug in Europe or the United 
States. 
On February 23, 2011, the European Medicines Agency (EMA) granted or-
phan drug designation for axitinib for the treatment of RCC [6]. 
Axitinib (Inlyta®) 
Axitinib, a TKI targeting 
VEGFR 
recommended daily 
dose: 5mg twice daily 
 
dose titration if 
tolerated/needed 
2nd-line treatment in 
mRCC 
not yet approved in 
Europe or USA 
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The US Food and Drug Administration (FDA) granted orphan drug desig-
nation for axitinib for the treatment of pancreatic cancer, for the treatment 
of follicular, medullary and anaplastic thyroid carcinoma and metastatic or 
locally advanced papillary thyroid cancer, in May 2007 [7]. In April 2011, 
Pfizer submitted a new drug application (NDA) for axitinib to the FDA. In 
December 2011 the FDA was seeking advice from the Oncologic Drugs Ad-
visory Committee regarding questions, whether the benefit in progression-
free survival (PFS) of the pivotal AXIS trial [3] was generated by a sub-
group of patients (cytokine pre-treated) and whether the benefit-risk profile 
is favourable for axitinib treated patients after failure of first-line systemic 
therapy in advanced RCC [8]. 
4 Burden of disease 
RCC is a type of kidney cancer that accounts for approximately 90% of all 
kidney cancers [9] and 2-3% of all adult malignant tumours [10]. RCC is 
generally divided into histological sub-types relevant for treatment choice 
and tumour management: 60-80% are clear cell, 10-15% papillary, 5-10% 
chromophobe and 5% rare subtypes (e.g. oncocytoma, Bellini duct (collect-
ing duct), etc.) [11]. 
Risk factors for developing RCC are tobacco smoke, which accounts for at 
least 39% of all cases in males, obesity, exposure to carcinogenic arsenic 
compounds and several other environmental chemicals [12]. Median age at 
time of diagnosis of RCC is 60 years and men are more often affected than 
women (2:1) [10]. 
More than 60% of RCC are diagnosed incidentally and only 6-10% show the 
classic triad of the symptoms haematuria, pain and flank mass [12-13]. Most 
patients present with systemic symptoms such as weight loss, abdominal 
pain, anorexia and fever and are diagnosed incidentally by using imaging to 
investigate a variety of non-specific symptoms [10, 12-13]. About 25% of pa-
tients have metastatic disease at time of diagnosis [9] and 20-30% of patients 
initially diagnosed with localized tumour relapse one or two years after sur-
gery. Of those relapsing after surgery, about 50-60% will develop distant me-
tastasis eventually [14]. 
The TNM (Tumour Node Metastasis) staging system is used for clinical 
staging of RCC, taking the size of tumour, involved lymph nodes and metas-
tasis into account [14]. The TNM staging system is on the one hand a prog-
nostic factor and plays on the other hand an important role in the selection 
of therapy [13]. In contrast to localized tumours with a high probability of 
cure (stage I/II), more advanced forms with either metastases in the regional 
lymph nodes (stage III) or with distant metastases (stage IV) of kidney can-
cer are linked to poor outcomes. Estimated average 5-year survival rate for 
patients ranges from 23% (stage IV) to 64% (stage III) [14]. 
orphan drug for mRCC 
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Risk stratification is important for choosing the most appropriate therapy. 
The most common model to predict short term survival is the Memorial 
Sloan-Kettering Cancer Centre or Motzer criteria (MSKCC) which are based 
on the absence or presence of five risk-factors or predictors, such as serum 
LDH greater than 1.5 times the upper limit of normal (ULN), haemoglobin 
level below normal, corrected serum calcium level above the ULN, time 
from diagnosis and nephrectomy to therapy of less than 1 year and low per-
formance status (Karnofsky performance status (KPS) <70%). Depending 
on the number of risk factors three groups can be stratified: a good, inter-
mediate or poor risk-group [14]. As the MSKCC criteria are developed and 
validated based on data derived from patients treated with immunotherapy 
it is currently unclear, whether and to what extend these prognostic factors 
are also relevant for patients treated with VEGF-targeted therapy. Thus, 
Heng et al. conducted a retrospective study to validate the existing MSKCC 
criteria and other prognostic factors aiming to create a simple clinical-
prediction model [15]. This model includes two clinical parameters (KPS 
<80% and time from diagnosis to treatment <1 year) and four laboratory 
parameters (hemoglobin <lower limit of normal (LLN), calcium >ULN, 
neutrophil count >ULN and platelet count >ULN) [15]. 
In 2009, 1,199 patients were newly diagnosed with kidney cancer in Austria. 
Men were more often affected than women with 707 cases and 492, respec-
tively [16]. Applying the above mentioned estimates, about 300 patients are 
newly diagnosed with mRCC in Austria per year. 
5 Current treatment 
Prior to the approval of six targeted agents within the past few years, con-
ventional immunotherapy with interferon (IFN) or interleukin-2 (IL-2) was 
the standard of therapy in mRCC [17]. While immunotherapy was active in 
many other cancers it had limited clinical benefit (with response rates be-
tween 10-20% [11]) in mRCC and caused considerable toxicities [18]. Since 
2006 six targeted agents with different mechanisms of action – TKIs (sunit-
inib, sorafenib and pazopanib), inhibitors or the mammalian target of rapa-
mycin (mTOR; everolimus, temsirolimus) and a monoclonal antibody 
(moAb; bevacizumab) – have been approved for the treatment of mRCC. 
TKIs (brand name), year of EMA approval: 
 Sunitinib (Sutent®), 2006 
 Sorafenib (Nexavar®), 2006 
 Pazopanib (Votrient®), 2010 
mTOR inhibitors (brand name), year of EMA approval: 
 Temsirolimus (Torisel®), 2007 
 Everolimus (Afinitor®), 2009 
Monoclonal antibody (brand name), year of EMA approval: 
 Bevacizumab (Avastin®), 2007 
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3 MSKCC risk groups: 
good, intermediate, 
poor 
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Within the clinical trials that led to approval of these agents, all drugs were 
either compared to IFN and/or placebo but not to another targeted agent. 
All of these new targeted agents bind to the VEGF receptor [19]. The study 
population of these pivotal trials was either cytokine-refractory or treat-
ment-naïve except for everolimus, which was compared to placebo in pa-
tients who were mainly sunitinib and/or sorafenib refractory [17]. 
According to the treatment guidelines by the National Comprehensive Can-
cer Network the following agents have a category 1 recommendation for sec-
ond-line therapy in stage IV mRCC with predominantly clear cell histology: 
 everolimus, 
 sorafenib, 
 sunitinib 
 and pazopanib. 
The three TKIs are recommended as second-line agents after failure of cyto-
kine-based therapy and everolimus, currently the only targeted agent explic-
itly approved and studied as second-line agent [17], is recommended after 
failure of a TKI as first-line agent [10, 14]. 
Currently, one of the main concerns in mRCC is to conduct head-to-head 
comparisons of the approved targeted agents and to find the optimal se-
quence of therapy for patients with certain characteristics. 
Besides axitinib, further agents like tivozanib and dovotinib are in clinical 
development [2]. 
6 Evidence 
In addition to a free text search including the websites of the EMA and of 
the US FDA, a literature search was conducted in Medline, EMBASE, 
DARE (Database of the Centre for Review Dissemination of the National 
Institute of Health) and Cochrane Central on November 15, 2011 by the 
LBI-HTA. 
Only randomized clinical trials which tested axitinib in the indication of in-
terest (i.e. second-line therapy in patients with advanced RCC) were in-
cluded in the evaluation of efficacy. For the evaluation of safety also uncon-
trolled trials which tested axitinib in the indication of interest regardless of 
the investigated outcomes were considered. 
Overall, one phase III trial, the AXIS trial [3], met the selection criteria for 
efficacy evaluation. For safety evaluation two further single-arm phase II 
trials [4-5] were included. No additional trials to those presented in the Ho-
rizon Scanning report of the Italian Horizon Scanning Project (IHSP) [20] 
were identified. 
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6.1 Efficacy and safety - Phase III studies 
Table 1: Summary of efficacy 
Study title Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma 
(AXIS): a randomised phase 3 Trial (Rini et al. 2011 [3]) 
Study  
identifier 
Study No: AXIS Trial, ClinicalTrials Identifier: NCT00678392; 
Sponsor Protocol Number: A4061032 
EudraCT Number: 2008-001451-21 
Phase III, randomised, open-label, multicentre (175 sites in 22 countries (USA, Poland, 
Russia, UK, France, Taiwan, Spain)), active-controlled trial 
Design 
Duration  Enrolment: Sept 2009 – July 2010 
Median follow-up: study still ongoing, (completion planned in 
2015) 
Cut-off date for analysis: Aug 31, 2010 
Final OS analysis: November 1, 2011 [21] 
Hypothesis Superiority – study is powered 90% on a one-sided log-rank test at a significance level of 
0.025 to show an improvement in PFS from 5 months with sorafenib to 7 months with 
axitinib 
Funding Pfizer Inc; involved in the design of the study, collection and analysis of the data 
Intervention (I) axitinib at a starting dose of 5 mg twice daily for ≥2 weeks. Then 
dose escalation to 7 mg twice daily and then to 10 mg twice daily. 
Higher doses should be used unless blood pressure was >150/90 
mmHg or patient was receiving anti-hypertensive medication. Ax-
itinib doses could be reduced to 3 mg twice daily and then to 2 mg 
twice daily, if needed. 
Treatment 
groups 
Control (C) starting dose of 400 mg twice daily. Dose could be reduced to 400 
mg once daily and then to 400 mg every other day, if needed be-
cause of toxic effects 
Progression free sur-
vival 
(primary endpoint) 
PFS time from randomisation to either first documented RECIST 
v1.0. -progression or all-cause death; assessed by an inde-
pendent, blinded radiology review committee 
Overall survival (sec-
ondary endpoint) 
OS time from randomisation to death from any cause 
Objective response 
rate (secondary end-
point) 
ORR according to RECIST v1.0. (Response Evaluation Criteria in 
Solid Tumours) 
Endpoints and 
definitions 
Duration of Response 
(secondary endpoint) 
DoR time from randomisation to RECIST v1.0. documentation 
 Time to deterioration TTD a composite endpoint defined as time between randomisa-
tion to first occurrence of death, disease progression, or 
worsening of symptoms either measured by a) FKSI-15 and 
b) FKSI-DRS 
 Functional Assess-
ment of Cancer Ther-
apy Kidney Symptom 
Index questionnaire 
FKSI assessments took place at baseline and at day 1 of every 4-
week cycle; symptom deterioration was defined as two con-
secutive available decreases of at least 5 points from base-
line unless it was the final score, for which one decrease was 
sufficient 
Horizon Scanning in Oncology 
8 LBI-HTA | 2012 
 FKSI–Disease-Related 
Symptoms 
FKSI-
DRS 
assessments took place at baseline and at day 1 of every 4-
week cycle; symptom deterioration was defined as two con-
secutive available decreases of at least 3 points from base-
line unless it was the final score, for which one decrease was 
sufficient 
Results and analysis 
Analysis  
description 
Efficacy population (n): 723 (ITT analysis) (Axitinib: 361 vs. Sorafenib: 362) 
Safety population (n): 714 
Characteristics Sex: Males I 73% vs C 71%, Females I 27% vs C 29%  
Ethnicity: White: I 77% vs C 74%, Black: I <1% vs C 1%, 
Asian I 21% vs C 22%, Other I 1% vs C 2% 
Median age (range): I 61 yrs (20-82 yrs) vs C 61 yrs (22-80 
yrs) 
ECOG-PS 0: I 54% vs C 55%; ECOG-PS 1/>1: I 45% / <1% vs 
C 44% / 0% 
MSKCC risk groups (%; favourable/intermediate/poor/NA): 
I 28/37/33/2 vs C 28/36/33/3 
Heng et al. risk factors (%, favourable/ intermediate/ poor/ 
NA): I 18/65/10/6 vs C 22/62/9/7 
Previous systemic therapy with: 
Sunitinib: I 54% vs C 54% 
Cytokines: I 35% vs C 35% 
Bevacizumab: I 8% vs C 8% 
Temsirolimus: I 3% vs C 3% 
Analysis  
population 
Inclusion criteria histologically or cytologically confirmed RCC with a clear-
cell 
component; all patients had measurable disease by Re-
sponse Evaluation Criteria in Solid Tumours (RECIST, ver-
sion 1.0) and RECIST-defined progressive disease as assessed 
by investigators after one previous systemic first-line regi-
men with a sunitinib-based, bevacizumab plus interferon-
alfa-based, temsirolimus-based, or cytokine-based regimen, 
which reflected all regimens with regulatory approvals at 
the time of study design; 
≥2 weeks since end of previous systemic treatment (≥4 
weeks for bevacizumab + interferon-alfa); 
ECOG PS: 0 or 1; 
life expectancy of 12 weeks or more; 
adequate renal, hepatic and haematological organ function.
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Exclusion criteria history of malignancy other than RCC; 
present use or anticipated need for CYP405-3A4-inducing, 
or CYP1A2-inducing drugs; 
known HIV or acquired immunodeficiency syndrome-
related disease; 
CNS metastasis; 
uncontrolled hypertension; 
myocardial infarction, uncontrolled angina, congestive 
heart failure, or cerebro-vascular accident within previous 
12 months; 
deep vein thrombosis or pulmonary embolism within previ-
ous 6 months. 
Treatment group Intervention 
(axitinib) 
Control 
(sorafenib) 
Number of subjects 361 362 
Median PFS, months 
95% CI 
6.7 
6.3 to 8.6 
4.7 
4.6 to 5.6 
Median PFS according to 
previous treatment, months 
(95% CI) 
Cytokine (34% of pts) 
Sunitinib (54% of pts) 
Bevacizumab (8% of pts)
Temsirolimus (3% of pts)
 
 
 
12.1 (10.1 to 13.9) 
4.8 (4.5 to 6.4) 
4.2 (2.8 to 6.5) 
10.1 (1.5 to 10.2) 
 
 
 
6.5 (6.3 to 8.3) 
3.4 (2.8 to 4.7) 
4.7 (2.8 to 6.7) 
5.3 (1.5 to 10.1) 
ORR, n (%) 
95% CI 
70 (19%) 
15.4 to 23.9 
34 (9%) 
6.6 to 12.9 
Best ORR, n (%) 
CR 
PR 
SD ≥20 weeks 
SD <20 weeks 
PD 
Indeterminate* 
 
0 
70 (19) 
96 (27) 
84 (23) 
78 (22) 
22 (6) 
 
0 
34 (9) 
77 (21) 
120 (33) 
76 (21) 
42 (12) 
Median DoR, months 
95% CI 
11 
7.4 to not estimable 
10.6 
8.8 to 11.5 
Median TTD by FKSI-15, 
months 
95% CI 
 
3.1 
2.8 to 4.5 
 
2.8 
2.7 to 3.0 
Median TTD by FKSI-DRS, 
months 
95% CI 
 
3.7 
2.8 to 4.6  
 
2.9 
2.8 to 3.5 
Descriptive 
statistics and 
estimated 
variability 
Median OS [21], months 
95% CI 
20.1 
16.7 to 23.4 
19.2 
17.5 to 22.3 
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Comparison groups  Intervention vs Control 
HR 0.665 
95% CI 0.544 to 0.182 
Median PFS 
P value <0.0001 
PFS according to previous 
treatment   
HR 
(95% CI, p-value) 
Cytokine 
 
Sunitinib 
 
Bevacizumab 
 
Temsirolimus 
 
 
0.464 
(0.318 to 0.676, p<0.0001) 
0.741 
(0.573 to 0.958, p = 0.0107)
1.147 
(0.568 to 2.317, p = 0.6366) 
0.511 
(0.140 to 1.865, p= 0.1425) 
HR - 
95% CI - 
ORR 
P value 0.0001 
HR 0.829 
95% CI 0.701 to 0.981 
Median TTD by FKSI-15 
P value 0.014# 
HR 0.838 
95% CI 0.707 to 0.993 
Median TTD by FKSI-DRS 
P value 0.0203# 
HR 0.969 
95% CI 0.800 to 1.174 
Effect esti-
mate per 
comparison 
Median OS 
P value 0.374 
 
*Indeterminate included patients with no post-baseline scans, target lesions that were indeterminate at subsequent 
timepoints, or patients randomised and not treated; #p-values based on one-sided log-rank test 
Abbreviations: ITT analysis – intention to treat analysis; vs – versus; yrs – years; ECOG-PS – Eastern Coop-
erative Oncology Group performance status; MSKCC – Memorial Sloan-Kettering Cancer Center; NA – not 
available; CR – complete response; PR – partial response; SD – stable disease; PD - progressive disease; HR – 
hazard ratio; 95% CI – 95% confidence interval 
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Table 2: Common treatment-emergent all-causality adverse events (AE) and overall AE overview 
Study ID NCT00678392 
Outcome 
Number of patients (%) 
Intervention (n=359) Control (n= 355) 
 All grades Grade ≥3 All grades Grade ≥3 
Diarrhoea 197 (55%) 38 (11%) 189 (53%) 26 (7%) 
Hypertension 145 (40%) 56 (16%) 103 (29%) 39 (11%) 
Fatigue 140 (39%) 41 (11%) 112 (32%) 18 (5%) 
Decreased appetite 123 (34%) 18 (5%) 101 (29%) 13 (4%) 
Nausea 116 (32%) 9 (3%) 77 (22%) 4 (1%) 
Dysphonia 111 (31%) 0 48 (14%) 0 
Palmar-plantar erythrody-
saesthesia 98 (27%) 18 (5%) 181 (51%) 57 (16%) 
Weight decreased 89 (25%) 8 (2%) 74 (21%) 5 (1%) 
Vomiting 85 (24%) 12 (3%) 61 (17%) 3 (1%) 
Asthenia 74 (21%) 19 (5%) 50 (14%) 9 (3%) 
Constipation 73 (20%) 4 (1%) 72 (20%) 3 (1%) 
Hypothyroidism 69 (19%) 1 (<1%) 29 (8%) 0 
Cough 55 (15%) 3 (1%) 59 (17%) 2 (1%) 
Mucosal inflammation 55 (15%) 5 (1%) 44 (12%) 2 (1%) 
Arthralgia 54 (15%) 5 (1%) 39 (11%) 5 (1%) 
Stomatitis 54 (15%) 5 (1%) 44 (12%) 1 (<1%) 
Rash 45 (13%) 1 (<1%) 112 (32%) 14 (4%) 
Grade 
(according to 
CTCAE ver-
sion 3.0) [22] 
Alopecia 14 (4%) 0 115 (32%) 0 
Haematology Laboratory Abnormalities* 
Anaemia 113/320 (35%) 1/320 (<1%) 165/316 (52%) 12/316 (4%) 
Haemoglobin elevation 31/320 (10%) NA 3/316 (1%) NA 
Neutropenia 19/316 (6%) 2/316 (1%) 26/308 (8%) 2/308 (1%) 
Thrombocytopenia 48/312 (15%) 1/312 (<1%) 44/310 (14%) 0 
 
Lymphopenia 106/317 (33%) 10/317 (3%) 111/309 (36%) 11/309 (4%) 
Chemistry laboratory abnormalities* 
Creatinine elevation 185/336 (55%) 0 131/318 (41%) 1/318 (<1%) 
Hypophosphataemia 43/336 (13%) 6/336 (2%) 158/318 (50%) 51/318 (16%)
Hypercalcaemia 19/336 (6%) 0 5/319 (2%) 0 
Hypocalcaemia 132/336 (39%) 4/336 (1%) 188/319 (59%) 5/319 (2%) 
 
Lipase elevation 91/338 (27%) 16/338 (5%) 148/319 (46%) 47/319 (15%)
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Overall Safety Overview, n (%) [21] 
Adverse Events 
Grade 3 
Grade 4 
342 (95) 
181 (50) 
21 (6) 
347 (98) 
182 (51) 
36 (10) 
Discontinuations due to 
AEs 
 
33 (9) 
 
46 (13) 
Serious AEs 106 (30) 24 (7) 
Deaths 113 (31) 109 (31) 
Deaths during treatment 
or within 28 days from 
last dose 
Due to disease progres-
sion 
Due to reason other 
than disease progres-
sion 
 
 
36 (10) 
 
26 (7) 
 
 
10 (3) 
 
 
24 (7) 
 
17 (5) 
 
 
7 (2) 
 
Treatment-related deaths  4 (1) 
 
5 (1) 
*Denominator for each laboratory abnormality differed depending on the availability of baseline and at least one on-
study test result. 
 
 
The phase III open-label AXIS trial (NCT00678392) [3] was conducted in 
723 patients (64% at intermediate risk according to Heng model [15]) with 
median age of 61 and with mRCC pretreated with sunitinib (54%), cytokine 
(35%), bevacizumab (8%) or temsirolimus (3%). Patients were randomised 
to receive oral axitinib (5 to 10 mg twice daily) or oral sorafenib (initial dos-
age of 400 mg twice daily).  
Major efficacy result of the pivotal AXIS trial is the statistically significant 
increase in median PFS of 2 months in the axitinib treated group compared 
to the control group (HR 0.665; 95% CI: 0.544 to 0.182; p<0.0001). Sub-
group analysis of median PFS according to previous treatment shows that 
the increase in PFS is even higher in patients pre-treated with cytokines 
(+5.6 months) and temsirolimus (+4.8 months) compared to pre-treatment 
with the VEGFR targeting agents sunitinib (+1.4 months) or bevacizumab 
(-0.5 months). Comparing the control and intervention group, the increase 
in median PFS was statistically significant in cytokine and sunitinib pre-
treated patients, not in bevacizumab or temsirolimus, which might be due to 
the small number of included patients within the subgroups. The objective 
response rate was higher in the axitinib group (19%) than in the sorafenib 
group (9%) and the median duration of response differed by 0.4 months be-
tween these two groups.  
723 pts (I 361 vs C 362) 
median age: 61 years 
>50% of pts were 
sunitinib pre-treated 
+2 months median PFS 
in axitinib arm vs. 
sorafenib 
 
+5.6 median PFS in pts 
pre-treated with 
cytokine compared to 
+1.4 in pts pre-treated 
with sunitinib 
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After progression on study treatment patients with progressive disease did 
not cross over to the other arm, but within the axitinib arm 26.7% (50 of 
187) who had progressed remained on axitinib and 28% (n=101) received a 
post-progression systemic therapy; 34.7% (74 of 214) of patients with pro-
gressive disease in the control arm remained on sorafenib and 36.7% 
(n=133) received a post-progression systemic therapy [8]. The different 
post-progression treatment regimens make it difficult to measure the effect 
of axitinib on overall survival (OS) compared to sorafenib as the subsequent 
active therapy cannot yet be statistically controlled and will influence OS to 
an extent that is difficult to quantify [18]. In December 2011 Pfizer pre-
sented the final OS data to the Oncologic Drugs Advisory Committee, which 
did not demonstrate superiority of axitinib over sorafenib (HR 0.969, 95% 
CI 0.800 to 1.174; p=0.376) with a median OS of 20.1 and 19.2 months in the 
axitinib and sorafenib groups, respectively [18]. 
The aspect of quality of life (QoL) was quantified using a composite end-
point consisting of time to death, disease progression, or worsening of symp-
toms. The latter was measured with the Functional Assessment of Cancer 
Therapy Kidney Symptom Index (FKSI) and the FKSI Disease-Related 
Symptoms (FKSI-DRS). Measurement of time to deterioration with both in-
struments lead to a risk reduction in the axitinib group compared to the 
sorafenib group of 17% and 16% with the FKSI-15 and FKSI-DRS ques-
tionnaire, respectively. 
Within the AXIS trial, main adverse events (AEs) with axitinib vs. sorafenib 
were diarrhoea (55% vs. 53%); hypertension (40% vs. 29%); fatigue (39% vs. 
32%); nausea (32 vs. 22%); dysphonia (31% vs. 14%); palmar-plantar 
erythrodysaesthesia (27% vs. 51%); vomiting (24% vs. 17%); asthenia (21% 
vs. 14%); hypothyroidism (19% vs. 8%); stomatitis (15% vs. 12%). Labora-
tory abnormalities more frequently found with axitinib than with sorafenib 
were haemoglobin elevation (10% vs. 1%); hypercalcaemia (6% vs. 2%); 
creatinine elevation (55% vs. 41%); thrombocytopenia (15% vs. 14%). 
Discontinuations due to AEs were 22 (6%) and 33 (9%) with axitinib and 
sorafenib, respectively and discontinuations due to treatment–related AEs 
were twice as frequent in the sorafenib group than in the axitinib group (I 
4% vs C 8%). No treatment-related deaths were observed in the axitinib 
group but two patients died in the sorafenib group. 
6.2 Further studies - safety 
Two single-arm, open-label phase II trials assessing the safety and efficacy of 
axitinib in 114 pre-treated patients were identified (NCT00282048) [4] 
(NCT00076011) [5]. Objective response rate (ORR according to RECIST cri-
teria) was the primary endpoint in both trials. ORR was 22.6% (95% CI 
12.9% to 35.0%) and 44.2% (95% CI 30.5% to 58.7%) within those two trials, 
respectively. 
Generally the most frequent reported AEs in single-agent axitinib trials are 
hypertension, fatigue and gastrointestinal toxicities [1]. In the trial with cy-
tokine-refractory patients, 28 of the 52 individuals (i.e. 54%) experienced 
treatment-related grade 3-4 AEs, the most common ones being hypertension 
(15%), diarrhoea (10%) and fatigue (8%) [5]. In sorafenib-pretreated pa-
tients the most common grade 3-4 AEs were fatigue, hypertension and hand-
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foot syndrome (each 16.1%), lymphopenia (16.4%) dyspnoea (12.9%), diar-
rhoea (14.5%) and abdominal pain (11.3%) [4]. 
7 Estimated costs 
No cost estimates for Inlyta® are available yet in Austria.  
The estimated monthly treatment costs for the other three approved TKIs 
range from € 3,300.- to € 5,500.- per month and for everolimus [9, 23-25], 
currently the only targeted agent approved for second-line therapy, esti-
mated monthly treatment costs are € 3,600.- [26]. It is thus rather likely that 
the costs for axitinib will also be within this price range. 
8 On-going research 
Regarding the investigated indication one on-going phase III RCTs was 
identified at www.clinicaltrial.gov [27] and www.clinicaltrialsregister.eu. 
Phase III trial 
NCT00920816: 
The study is designed to demonstrate that axitinib (AG-013736) is supe-
rior to sorafenib in delaying tumour progression in patients with metas-
tatic renal cell cancer. The estimated primary completion date is April 
2012. 
Additional, several phase II trials investigating axitinib in RCC are regis-
tered at ClinicalTrials.gov. Further, several other phase I and II studies are 
currently conducted and registered at ClinicalTrials.gov in different indica-
tions such as hepatocellular carcinoma, non-squamous non-small cell lung 
cancer, prostate cancer, melanoma or metastatic colorectal cancer.  
9 Commentary  
Inlyta® (Axitinib) is not yet approved for anticancer treatment in Europe or 
the United States. According to the registered clinical trials at 
www.clinicaltrial.gov the anti-tumour effect of axitinib is investigated in a 
variety of cancer types in phase I to III clinical trials.  
The FDA currently reviews Pfizer’s approval application of axitinib for the 
second-line treatment of axitinib after failure of first-line systemic therapy 
based on the efficacy and safety results of the pivotal AXIS trial [3, 8]. 
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The AXIS trial is the first head-to-head comparison of VEGFR targeting 
TKIs in the treatment of RCC and it is also the first trial that explicitly 
compares two active VEGFR comparators in the second-line setting [21]. 
The rationale of the AXIS trial was that due to a more precise selectivity of 
axitinib for the VEGFR compared to multi-targeted TKIs like sorafenib, 
sunitinib or pazopanib, axitinib would improve treatment outcomes and tox-
icity profiles. Due to the fact that these multi-targeted TKIs inhibit a wide 
range of other tyrosine kinases and other targets besides the VEGFR, several 
toxicities that are generally unrelated to the VEGF pathway are observed 
within clinical trials. These toxicities are often termed as “off-target” effects 
of multi-targeted TKIs [2]. 
Although, everolimus, an oral mTOR inhibitor, is currently the only tar-
geted agent explicitly licensed for second-line treatment of advanced RCC, 
sorafenib was chosen as the active comparator as it was considered to be 
standard of care at the time of AXIS trial initiation and everolimus was still 
in clinical development [3, 8]. It has to be noted though, that sorafenib was 
licensed and studied in mRCC patients when immunotherapy with IFN or 
IL-2 failed [9], but >50% of the AXIS study population were sunitinib-
refractory, a population in which the efficacy of sorafenib has not been in-
vestigated in a phase III trial yet. 
The primary outcome of the AXIS trial, median PFS, was statistically sig-
nificantly increased by 2 months in the axitinib group compared to the 
sorafenib group. An analysis of median PFS according to the type of pre-
treatment patients had received, raises the question whether the PFS benefit 
is driven by the 35% of patients pre-treated with cytokines (difference in 
median PFS: 5.6 months; compared to the median PFS increase of 1.4 
months in sunitinib pre-treated patients) [8]. ORR was higher in the inter-
vention group (19%) compared to the control group (9%), but no complete 
responses were observed in any group [8]. 
Overall, the frequency and severity of AEs were comparable between axit-
inib and sorafenib. The most frequent (>10%) grade 3 or 4 AEs were hyper-
tension, diarrhoea and fatigue in the axitinib group and hypertension and 
palmar-plantar erythrodysaesthesia in the sorafenib group. More patients in 
the sorafenib group (13%) discontinued treatment due to AEs than in the in-
tervention group (9%), but serious AEs were more frequent in the axitinib 
group (31%) than in the sorafenib group (7%).  
Limitations of the AXIS trial are, on the one hand, the open-label design, 
which has the potential to bias the assessment of toxic effects and QoL and, 
on the other hand, that dose escalations were allowed in the intervention 
arm only when treatment was well tolerated as mentioned by the investiga-
tors but not in the control arm [3]. 
As already briefly mentioned above, due to the availability of multiple lines 
of therapy for the treatment of RCC and due to cross-over within several 
clinical trials, it is problematic to accurately assess the effect of a specific 
therapy on survival. Thus, regulatory agencies have accepted PFS as a pri-
mary outcome in RCC, despite the absence of universally accepted data con-
firming that PFS is a valid surrogate for OS [28]. 
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To date, no curative therapy exists for advanced RCC [10]. Thus, the aim of 
treatment is symptom palliation, improvement of QoL and extension of OS. 
With the availability of different therapeutic options, future research should 
focus on the specific management of RCC patients in terms of establishing 
an optimal sequence of the available drugs and adverse event management 
[18]. Schmidinger et al. [18] state that the side-effect profiles and the 
mechanisms of action of these novel agents are crucial for the development 
of treatment strategies in order to avoid overlapping toxicities and to enable 
a more rational approach for patient selection. This approach could spare 
patients unnecessary side effects. 
One way of improving outcomes of patients with mRCC might be to com-
bine agents that target different receptors [11], even though it is unclear 
which combination is the most efficacious and safe regimen which simulta-
neously maintains or improves QoL [11, 18]. 
To sum up, the AXIS trial reached its goal to significantly improve median 
PFS with axitinib by 2 months compared to sorafenib; difference in median 
OS was not significant. Sub-group analyses indicate that the treatment effect 
of both VEGFR targeting agents, axitinib and sorafenib, was less pro-
nounced in the sub-group of patients that failed prior TKI therapy with 
sunitinib. Thus, the question remains whether axitinib should be recom-
mended for the treatment in patients pre-treated with a TKI targeting 
VEGFR and how the effectiveness and AE profiles compares to everolimus, 
the current standard of care in second-line treatment of mRCC after failure 
of VEGFR targeting TKIs.  
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